PRNewswire (Wed, 26-Aug 10:51 AM ET)
MeiraGTx Reports Second Quarter 2026 Financial and Operational Results
Globe Newswire (Thu, 13-Aug 8:00 AM ET)
PRNewswire (Tue, 11-Aug 10:30 AM ET)
MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Thu, 6-Aug 4:30 PM ET)
Market Chameleon (Tue, 7-Jul 3:50 AM ET)
Globe Newswire (Tue, 7-Jul 7:30 AM ET)
MeiraGTx’s $100 Million Share Offering Sets Stage for Key Clinical Milestones Into 2028
Market Chameleon (Thu, 16-Apr 4:38 AM ET)
MeiraGTx’s Breakthrough Collaboration With Lilly Targets Vision Restoration for Children
Market Chameleon (Mon, 10-Nov 3:09 AM ET)
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.
Meiragtx Holdings PLC - trades on the NASDAQ stock market under the symbol MGTX.
As of September 9, 2026, MGTX stock price declined to $13.26 with 516,196 million shares trading.
MGTX has a beta of 2.16, meaning it tends to be more sensitive to market movements. MGTX has a correlation of 0.24 to the broad based SPY ETF.
MGTX has a market cap of $1.27 billion. This is considered a Small Cap stock.
Last quarter Meiragtx Holdings PLC - reported $321 million in Revenue and $1.71 earnings per share. This beat revenue expectation by $313 million and exceeded earnings estimates by $2.13.
In the last 3 years, MGTX traded as high as $15.35 and as low as $3.49.
The top ETF exchange traded funds that MGTX belongs to (by Net Assets): JSML, JSMD, VTWO, KOMP, VHT.
MGTX has outperformed the market in the last year with a return of +77.5%, while the SPY ETF gained +18.7%. In the last 3 month period, MGTX beat the market returning +45.9%, while SPY returned +3.4%. However, in the most recent 2 weeks MGTX has underperformed the stock market by returning -11.1%, while SPY returned -0.5%.
MGTX support price is $13.14 and resistance is $13.92 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MGTX shares will trade within this expected range on the day.